Loading...
XNAS
ITCI
Market cap14bUSD
Apr 01, Last price  
131.87USD
Name

Intra-Cellular Therapies Inc

Chart & Performance

D1W1MN
P/E
—
P/S
20.63
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.32%
Rev. gr., 5y
545.80%
Revenues
681m
+46.62%
3,117,9912,737,002577,30191,364330,702245,837060,61322,530,75381,707,874249,132,000464,370,000680,852,000
Net income
-75m
L-46.54%
-16,590,827-26,868,198-30,691,460-104,793,141-116,426,268-97,773,414-155,127,411-147,722,178-227,005,663-284,125,666-256,256,000-139,674,000-74,676,000
CFO
-73m
L-41.08%
-18,902,937-22,591,265-22,807,150-102,279,965-91,257,227-80,491,812-118,169,113-127,983,241-230,072,845-259,543,485-270,186,000-124,199,000-73,177,000
Earnings
Aug 05, 2025

Profile

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
URL
https://www.intracellulartherapies.com/
IPO date
Jan 31, 2014
Employees
561
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
680,852
46.62%
464,370
86.40%
249,132
204.91%
Cost of revenue
293,084
623,751
513,940
Unusual Expense (Income)
NOPBT
387,768
(159,381)
(264,808)
NOPBT Margin
56.95%
Operating Taxes
473
636
6
Tax Rate
0.12%
NOPAT
387,295
(160,017)
(264,814)
Net income
(74,676)
-46.54%
(139,674)
-45.49%
(256,256)
-9.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
543,086
17,810
455,159
BB yield
-6.31%
-0.26%
-9.15%
Debt
Debt current
4,233
7,224
4,567
Long-term debt
29,729
30,264
35,515
Deferred revenue
Other long-term liabilities
Net debt
(967,104)
(460,453)
(551,823)
Cash flow
Cash from operating activities
(73,177)
(124,199)
(270,186)
CAPEX
(322)
(269)
(778)
Cash from investing activities
(335,150)
105,541
(128,373)
Cash from financing activities
567,508
17,810
455,159
FCF
335,691
(145,766)
(316,306)
Balance
Cash
1,001,066
497,941
591,905
Long term investments
Excess cash
967,023
474,722
579,448
Stockholders' equity
(1,691,634)
(1,617,046)
(1,481,667)
Invested Capital
2,857,075
2,229,020
2,157,778
ROIC
15.23%
ROCE
33.27%
EV
Common stock shares outstanding
103,131
95,882
94,047
Price
83.52
16.62%
71.62
35.34%
52.92
1.11%
Market cap
8,613,503
25.43%
6,867,049
37.98%
4,976,950
17.03%
EV
7,646,399
6,406,596
4,425,127
EBITDA
379,247
(158,853)
(264,152)
EV/EBITDA
20.16
Interest
7,376
Interest/NOPBT